Education
About Us
Working with TipRanks
Follow Us
Botanix Pharmaceuticals Limited (AU:BOT)
ASX:BOT
BOT Stock Chart & Stats
AU$0.13
>-AU$0.01(-1.09%)
At close: 4:00 PM EST
AU$0.13
>-AU$0.01(-1.09%)
Day’s Range― - ―
52-Week RangeAU$0.11 - AU$0.54
Previous CloseN/A
Volume8.15M
Average Volume (3M)8.47M
Market Cap
AU$256.19M
Enterprise ValueAU$562.64M
Total Cash (Recent Filing)AU$64.97M
Total Debt (Recent Filing)AU$32.51M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Mar 04, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,970,660,000
10 Day Avg. Volume7,344,780
30 Day Avg. Volume8,473,310
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)7.26
Price to Sales (P/S)101.98
P/FCF Ratio-7.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.14Price Target Upside776.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue for the year was $5.76 million, beating our estimate of $2 million.
Market ExpansionSofdra's U.S. launch has shown rapid growth with significant momentum in patient uptake and physician prescriptions.
Strategic PartnershipsBotanix announced that its sublicensee in South Korea, Dongwha Pharm, received South Korean regulatory approval for Sofpironium Bromide for the treatment of primary axillary hyperhidrosis.
Bears Say
Market ChallengesA common challenge in the PAH space is that it remains underdiagnosed by both patients and physicians, limiting uptake of therapies.
Botanix Pharmaceuticals Limited News
BOT FAQ
What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
Botanix Pharmaceuticals Limited lowest share price was AU$0.10 and its highest was AU$0.54 in the past 12 months.
What is Botanix Pharmaceuticals Limited’s market cap?
Botanix Pharmaceuticals Limited’s market cap is AU$256.19M.
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
Botanix Pharmaceuticals Limited’s upcoming earnings report date is Mar 04, 2026 which is in 110 days.
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Botanix Pharmaceuticals Limited released its earnings results on Aug 29, 2025. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.02.
Is Botanix Pharmaceuticals Limited overvalued?
According to Wall Street analysts Botanix Pharmaceuticals Limited’s price is currently Undervalued.
Does Botanix Pharmaceuticals Limited pay dividends?
Botanix Pharmaceuticals Limited does not currently pay dividends.
What is Botanix Pharmaceuticals Limited’s EPS estimate?
Botanix Pharmaceuticals Limited’s EPS estimate is -0.02.
How many shares outstanding does Botanix Pharmaceuticals Limited have?
Botanix Pharmaceuticals Limited has 1,970,660,000 shares outstanding.
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Botanix Pharmaceuticals Limited reported an EPS of -AU$0.03 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:BOT
Botanix Pharmaceuticals Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.14 (776.92% Upside)
AU$1.14 (776.92% Upside)
Blogger Sentiment
Bullish
AU:BOT Sentiment 95%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.57%
12-Months-Change
Fundamentals
Return on Equity
-90.93%
Trailing 12-Months
Asset Growth
14.79%
Trailing 12-Months
Company Description
Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
BOT Stock 12 Month Forecast
Average Price Target
AU$1.14
▲(776.92% Upside)
Technical Analysis
Options Prices
Currently, No data available
---